Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
HCLS1-binding protein 3 (HS1BP3)
- Target
- HS1BP3
- Molecular classification
- Adaptor/Scaffold protein (binds other proteins and modulates signaling), Other (not classified as receptor, enzyme, ion channel, transporter, or transcription factor)
01
Overview
HCLS1-binding protein 3 (HS1BP3) is a human protein encoded by the HS1BP3 gene on chromosome 2p24.1. It is an adaptor/scaffold protein that interacts with the hematopoietic lineage cell-specific protein HS1 via SH3 domains, suggesting a role in modulating lymphocyte activation and intracellular signaling pathways such as IL-2 signaling. HS1BP3 also binds members of the 14-3-3 protein family—prominent in neuronal cells—and may regulate apoptosis and stimulate AP-1-mediated transcription. While mutations in HS1BP3 have been connected to hereditary essential tremor, direct involvement in other diseases is not well-established, and no drugs currently target HS1BP3 for therapeutic intervention.
- Other names
- HCLS1-binding protein 3HS1BP3HSP1BP-3HS1-BP3FLJ14249ETM2Mouse ortholog: Hs1bp3
02
Mechanism of action
Not applicable; no drugs currently target HS1BP3, so no mechanisms can be listed.
03
Biological functions
Modulation of signaling: May modulate IL-2 signalingProtein-protein interactions: Binds 14-3-3 family members, associating with motor neurons and Purkinje cellsLymphocyte activation: May be involved in immune response via interaction with HCLS1/HS1 proteinsApoptosis regulation: May regulate apoptosis via HS1Stimulation of AP-1-mediated transcription
04
Disease associations
Hereditary essential tremor (types 1 and 2)Potential involvement in apoptosis and immune-related disease pathways, though no direct evidence for major common diseases like cancer or cardiovascular disease
05
Safety considerations
None reported; as HS1BP3 is not a current therapeutic target, specific safety, toxicity, or on-target adverse effects are not described in biomedical literature.
06
Interacting drugs
No drugs are currently listed as interacting with HS1BP3 in available pharmacological databases or literature. No approved therapeutics target this molecule specifically.
07
Biomarkers
None established for HS1BP3 in patient selection or efficacy monitoring, based on available resources.
Beyond the preview
Go deeper on HCLS1-binding protein 3 (HS1BP3).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HCLS1-binding protein 3 (HS1BP3).